The influence of QRS duration and resynchronization status on the efficacy and safety of omecamtiv mecarbil in heart failure with reduced ejection fraction: the GALACTIC-HF trial
10 May 2026 (14:39 - 14:48)
Organised by: 
About the speaker
Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
4 More presentations in this session
Doctor D. Da Silva Correia (Lisbon, PT)
Doctor G. Mendieta Badimon (Barcelona, ES)
Doctor X. Wang (Boston, US)
Doctor N. Grote Beverborg (Groningen, NL)
Access the full session
The Event
Heart Failure 2026
10 May 2026
14:39 CET
You may be interested in
Congress Presentation
Congress Presentation
